← Back to patent-cliff list
Brensocatib
Tier C — Watch / tradeBrensocatib
AstraZeneca
Originator
2025
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CTSC
Brand：Brinsupri
Indications (approved)：Bronchiectasis, Lung disease
Regional status
US
Approved
2025-08-12
EU
Approved
2025-11-18
China
-
Japan
Approved
2026-08-24
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Brensocatib?
Approved indications include: Bronchiectasis, Lung disease.
When does the Brensocatib patent expire?
No public expiry year is available for Brensocatib yet; this page updates once verified.
How do I get a quote for Brensocatib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01